2023

Willett, B. J. et al. (2023) Omicron BA.2.86 cross-neutralising activity in community sera from the UK. Lancet, 402(10417), pp. 2075-2076. (doi: 10.1016/s0140-6736(23)02397-8) (PMID:37952549)

Jones, S. et al. (2023) SARS-CoV-2 in domestic UK cats from Alpha to Omicron: Swab surveillance and case reports. Viruses, 15(8), 1769. (doi: 10.3390/v15081769) (PMID:37632111) (PMCID:PMC10459977)

Tyson, G. B. et al. (2023) Increase in SARS-CoV-2 seroprevalence in UK domestic felids despite weak immunogenicity of post-Omicron variants. Viruses, 15(8), 1661. (doi: 10.3390/v15081661) (PMID:37632004) (PMCID:PMC10458763)

Tyson, G. B., Jones, S., Logan, N., McDonald, M., Marshall, L., Murcia, P. R. , Willett, B. J. , Weir, W. and Hosie, M. J. (2023) SARS-CoV-2 seroprevalence and cross-variant antibody neutralization in cats, United Kingdom. Emerging Infectious Diseases, 29(6), pp. 1223-1227. (doi: 10.3201/eid2906.221755) (PMID:37141617) (PMCID:PMC10202862)

Martin, C. A. et al. (2023) Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis. EClinicalMedicine, 58, 101926. (doi: 10.1016/j.eclinm.2023.101926) (PMID:37034357) (PMCID:PMC10071048)

Manali, M. et al. (2023) SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity. Journal of Infectious Diseases, 227(1), pp. 40-49. (doi: 10.1093/infdis/jiac332) (PMID:35920058) (PMCID:PMC9384671)

Liew, F. et al. (2023) SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine, 87, 104402. (doi: 10.1016/j.ebiom.2022.104402) (PMID:36543718) (PMCID:PMC9762734)

2022

Willett, B. J. et al. (2022) Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 7, 1709. (doi: 10.1038/s41564-022-01241-6) (PMID:36114232) (PMCID:PMC9483304)

Parry, H. et al. (2022) Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people. Cell Reports Medicine, 3(9), 100739. (doi: 10.1016/j.xcrm.2022.100739) (PMID:36075216) (PMCID:PMC9404227)

Hu, S., Logan, N., Coleman, S., Evans, C., Willett, B. J. and Hosie, M. J. (2022) Correlating IgG levels with neutralising antibody levels to indicate clinical protection in healthcare workers at risk during a measles outbreak. Viruses, 14(8), 1716. (doi: 10.3390/v14081716) (PMID:36016338) (PMCID:PMC9415042)

Willett, B. J. et al. (2022) SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 7(8), pp. 1161-1179. (doi: 10.1038/s41564-022-01143-7) (PMID:35798890) (PMCID:PMC9352574)

Parry, H. et al. (2022) COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia. Cancer Cell, 40(6), pp. 584-586. (doi: 10.1016/j.ccell.2022.05.001) (PMID:35588735) (PMCID:PMC9072807)

Dowell, A. C. et al. (2022) mRNA or ChAd0x1 COVID-19 vaccination of adolescents induces robust antibody and cellular responses with continued recognition of omicron following mRNA-1273. Frontiers in Immunology, 13, 882515. (doi: 10.3389/fimmu.2022.882515) (PMID:35720281) (PMCID:PMC9201026)

Hu, S., Logan, N., Puenpa, J., Wanlapakorn, N., Vongpunsawad, S., Poovorawan, Y., Willett, B. J. and Hosie, M. J. (2022) Evaluation of the effect of maternally derived antibody on response to MMR vaccine in Thai infants. Vaccine, 40(10), pp. 1439-1447. (doi: 10.1016/j.vaccine.2022.01.049) (PMID:35135700) (PMCID:PMC8884255)

Parry, H. et al. (2022) Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia. Journal of Hematology and Oncology, 15(1), 3. (doi: 10.1186/s13045-021-01219-7) (PMID:35000597) (PMCID:PMC8743056)

Dowell, A. C. et al. (2022) Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nature Immunology, 23(1), pp. 40-49. (doi: 10.1038/s41590-021-01089-8) (PMID:34937928) (PMCID:PMC8709786)

2021

Davis, C. et al. (2021) Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathogens, 17(12), e1010022. (doi: 10.1371/journal.ppat.1010022) (PMID:34855916) (PMCID:PMC8639073)

Morgan, D. C. et al. (2021) Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalisation. Peptide Science, 113(4), e24217. (doi: 10.1002/pep2.24217) (PMID:33615115) (PMCID:PMC7883042)

Hughes, E. C. et al. (2021) Severe Acute Respiratory Syndrome Coronavirus 2 serosurveillance in a patient population reveals differences in virus exposure and antibody-mediated immunity according to host demography and healthcare setting. Journal of Infectious Diseases, 223(6), pp. 971-980. (doi: 10.1093/infdis/jiaa788) (PMID:33367847) (PMCID:PMC7798933)

2020

Gilbert, M. et al. (2020) Distemper, extinction and vaccination of the Amur tiger. Proceedings of the National Academy of Sciences of the United States of America, 117(50), pp. 31954-31962. (doi: 10.1073/pnas.2000153117) (PMID:33229566) (PMCID:PMC7749280)

2018

Abdullah, N. et al. (2018) Structure-guided identification of a non-human morbillivirus with zoonotic potential. Journal of Virology, 92(23), e01248-18. (doi: 10.1128/JVI.01248-18) (PMID:30232185) (PMCID:PMC6232486)

2017

Hosie, M. J. , Techakriengkrai, N., Beczkowski, P. M., Harris, M., Logan, N. and Willett, B. (2017) The comparative value of feline virology research: can findings from the feline lentiviral vaccine be translated to humans? Veterinary Sciences, 4(1), 7. (doi: 10.3390/vetsci4010007)

2016

Logan, N., Dundon, W. G., Diallo, A., Baron, M. D., Nyarobi, M. J., Cleaveland, S. , Keyyu, J., Fyumagwa, R., Hosie, M. J. and Willett, B. J. (2016) Enhanced immunosurveillance for animal morbilliviruses using vesicular stomatitis virus (VSV) pseudotypes. Vaccine, 34(47), pp. 5736-5743. (doi: 10.1016/j.vaccine.2016.10.010) (PMID:27742221) (PMCID:PMC5084683)

Holzer, B., Hodgson, S., Logan, N., Willett, B. and Baron, M. D. (2016) Protection of cattle against rinderpest by vaccination with wild-type but not attenuated strains of peste des petits ruminants virus. Journal of Virology, 90(10), pp. 5152-5162. (doi: 10.1128/jvi.00040-16) (PMID:26984722) (PMCID:PMC4859729)

Logan, N. et al. (2016) Efficient generation of vesicular stomatitis 1 virus (VSV)-pseudotypes bearing morbilliviral glycoproteins and their use in quantifying virus neutralising antibodies. Vaccine, 34(6), pp. 814-822. (doi: 10.1016/j.vaccine.2015.12.006) (PMID:6706278)

2015

Beczkowski, P., Logan, N., McMonagle, E., Litster, A., Willett, B. J. and Hosie, M. J. (2015) An investigation of the breadth of neutralising antibody response in cats naturally infected with feline immunodeficiency virus. Journal of General Virology, 96(3), pp. 671-680. (doi: 10.1099/vir.0.071522-0) (PMID:25395594) (PMCID:PMC4336861)

2014

Beczkowski, P. M., Techakriengkrai, N., Logan, N., McMonagle, E., Litster, A., Willett, B. J. and Hosie, M. J. (2014) Emergence of CD134 cysteine-rich domain 2 (CRD2)-independent strains of feline immunodeficiency virus (FIV) is associated with disease progression in naturally infected cats. Retrovirology, 11, p. 95. (doi: 10.1186/s12977-014-0095-7) (PMID:25430586) (PMCID:PMC4275942)

2013

Willett, B.J. , Kraase, M., Logan, N., McMonagle, E., Varela, M. and Hosie, M.J. (2013) Selective expansion of viral variants following experimental transmission of a reconstituted feline immunodeficiency virus quasispecies. PLoS ONE, 8(1), e54871. (doi: 10.1371/journal.pone.0054871) (PMID:23372784) (PMCID:PMC3553009)

2011

Teixeira, B.M., Logan, N., Samman, A., Miyashiro, S.I., Brandão, P.E., Willett, B.J. , Hosie, M.J. and Hagiwara, M.K. (2011) Isolation and partial characterization of Brazilian samples of feline immunodeficiency virus. Virus Research, 160(1-2), pp. 59-65. (doi: 10.1016/j.virusres.2011.05.007)

Dietrich, I., McMonagle, E. L., Petit, S. J., Vijayakrishnan, S. , Logan, N., Chan, C. N., Towers, G. J., Hosie, M. J. and Willett, B. J. (2011) Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection. Journal of Virology, 85(12), pp. 5840-5852. (doi: 10.1128/JVI.00071-11) (PMID:21490095) (PMCID:PMC3126296)

Samman, A., McMonagle, E.L., Logan, N., Willett, B.J. , Biek, R. and Hosie, M.J. (2011) Phylogenetic characterisation of naturally occurring feline immunodeficiency virus in the United Kingdom. Veterinary Microbiology, 150(3-4), pp. 239-247. (doi: 10.1016/j.vetmic.2011.01.027)

2010

Willett, B. J., Kraase, M., Logan, N., McMonagle, E. L., Samman, A. and Hosie, M. J. (2010) Modulation of the virus-receptor interaction by mutations in the V5 loop of feline immunodeficiency virus (FIV) following in vivo escape from neutralising antibody. Retrovirology, 7(1), p. 38. (doi: 10.1186/1742-4690-7-38) (PMID:20420700) (PMCID:PMC2873508)

Kraase, M., Sloan, R., Klein, D., Logan, N., McMonagle, L., Biek, R. , Willett, B. J. and Hosie, M. J. (2010) Feline immunodeficiency virus env gene evolution in experimentally infected cats. Veterinary Immunology and Immunopathology, 134(1-2), pp. 96-106. (doi: 10.1016/j.vetimm.2009.10.015) (PMID:19897254)

Samman, A., Logan, N., McMonagle, E. L., Ishida, T., Mochizuki, M., Willett, B. J. and Hosie, M. J. (2010) Neutralization of feline immunodeficiency virus by antibodies targeting the V5 loop of Env. Journal of General Virology, 91(1), pp. 242-249. (doi: 10.1099/vir.0.015404-0)

2009

Willett, B. J., McMonagle, E. L., Logan, N., Schneider, P. and Hosie, M. J. (2009) Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus. Molecular Immunology, 46(6), pp. 1020-1030. (doi: 10.1016/j.molimm.2008.08.271)

2008

McEwan, W. A., McMonagle, E. L., Logan, N., Serra, R. C., Kat, P., Vandewoude, S., Hosie, M. J. and Willett, B. J. (2008) Genetically divergent strains of feline immunodeficiency virus from the domestic cat (Felis catus) and the African lion (Panthera leo) share usage of CD134 and CXCR4 as entry receptors. Journal of Virology, 82(21), pp. 10953-10958. (doi: 10.1128/JVI.01312-08)

Willett, B. J., McMonagle, E. L., Logan, N., Samman, A. and Hosie, M. J. (2008) A single site for N-linked glycosylation in the envelope glycoprotein of feline immunodeficiency virus modulates the virus-receptor interaction. Retrovirology, 5(77), (doi: 10.1186/1742-4690-5-77)

2007

Willett, B.J., McMonagle, E.L., Logan, N., Spiller, O.B., Schneider, P. and Hosie, M.J. (2007) Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. Journal of Virology, 81(18), pp. 9665-9679. (doi: 10.1128/JVI.01020-07)

2005

Logan, N., Graham, A., Zhao, X., Fisher, R., Maiti, B., Leone, G. and La Thangue, N. B. (2005) E2F-8: an E2F family member with a similar organization of DNA-binding domains to E2F-7. Oncogene, 24(31), pp. 5000-5004. (doi: 10.1038/sj.onc.1208703) (PMID:15897886)

2004

Logan, N., Delavaine, L., Graham, A., Reilly, C., Wilson, J., Brummelkamp, T. R., Hijmans, E. M., Bernards, R. and La Thangue, N. B. (2004) E2F-7: a distinctive E2F family member with an unusual organization of DNA-binding domains. Oncogene, 23(30), pp. 5138-5150. (doi: 10.1038/sj.onc.1207649) (PMID:15133492)

2000

Logan, N., Reilly, J.J., Grant, S. and Paton, J.Y. (2000) Resting heart rate definition and its effect on apparent levels of physical activity in young children. Medicine and Science in Sports and Exercise, 32(1), pp. 162-166.

Articles

Willett, B. J. et al. (2023) Omicron BA.2.86 cross-neutralising activity in community sera from the UK. Lancet, 402(10417), pp. 2075-2076. (doi: 10.1016/s0140-6736(23)02397-8) (PMID:37952549)

Jones, S. et al. (2023) SARS-CoV-2 in domestic UK cats from Alpha to Omicron: Swab surveillance and case reports. Viruses, 15(8), 1769. (doi: 10.3390/v15081769) (PMID:37632111) (PMCID:PMC10459977)

Tyson, G. B. et al. (2023) Increase in SARS-CoV-2 seroprevalence in UK domestic felids despite weak immunogenicity of post-Omicron variants. Viruses, 15(8), 1661. (doi: 10.3390/v15081661) (PMID:37632004) (PMCID:PMC10458763)

Tyson, G. B., Jones, S., Logan, N., McDonald, M., Marshall, L., Murcia, P. R. , Willett, B. J. , Weir, W. and Hosie, M. J. (2023) SARS-CoV-2 seroprevalence and cross-variant antibody neutralization in cats, United Kingdom. Emerging Infectious Diseases, 29(6), pp. 1223-1227. (doi: 10.3201/eid2906.221755) (PMID:37141617) (PMCID:PMC10202862)

Martin, C. A. et al. (2023) Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis. EClinicalMedicine, 58, 101926. (doi: 10.1016/j.eclinm.2023.101926) (PMID:37034357) (PMCID:PMC10071048)

Manali, M. et al. (2023) SARS-CoV-2 evolution and patient immunological history shape the breadth and potency of antibody-mediated immunity. Journal of Infectious Diseases, 227(1), pp. 40-49. (doi: 10.1093/infdis/jiac332) (PMID:35920058) (PMCID:PMC9384671)

Liew, F. et al. (2023) SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine, 87, 104402. (doi: 10.1016/j.ebiom.2022.104402) (PMID:36543718) (PMCID:PMC9762734)

Willett, B. J. et al. (2022) Publisher Correction: SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 7, 1709. (doi: 10.1038/s41564-022-01241-6) (PMID:36114232) (PMCID:PMC9483304)

Parry, H. et al. (2022) Vaccine subtype and dose interval determine immunogenicity of primary series COVID-19 vaccines in older people. Cell Reports Medicine, 3(9), 100739. (doi: 10.1016/j.xcrm.2022.100739) (PMID:36075216) (PMCID:PMC9404227)

Hu, S., Logan, N., Coleman, S., Evans, C., Willett, B. J. and Hosie, M. J. (2022) Correlating IgG levels with neutralising antibody levels to indicate clinical protection in healthcare workers at risk during a measles outbreak. Viruses, 14(8), 1716. (doi: 10.3390/v14081716) (PMID:36016338) (PMCID:PMC9415042)

Willett, B. J. et al. (2022) SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 7(8), pp. 1161-1179. (doi: 10.1038/s41564-022-01143-7) (PMID:35798890) (PMCID:PMC9352574)

Parry, H. et al. (2022) COVID-19 vaccines elicit robust cellular immunity and clinical protection in chronic lymphocytic leukemia. Cancer Cell, 40(6), pp. 584-586. (doi: 10.1016/j.ccell.2022.05.001) (PMID:35588735) (PMCID:PMC9072807)

Dowell, A. C. et al. (2022) mRNA or ChAd0x1 COVID-19 vaccination of adolescents induces robust antibody and cellular responses with continued recognition of omicron following mRNA-1273. Frontiers in Immunology, 13, 882515. (doi: 10.3389/fimmu.2022.882515) (PMID:35720281) (PMCID:PMC9201026)

Hu, S., Logan, N., Puenpa, J., Wanlapakorn, N., Vongpunsawad, S., Poovorawan, Y., Willett, B. J. and Hosie, M. J. (2022) Evaluation of the effect of maternally derived antibody on response to MMR vaccine in Thai infants. Vaccine, 40(10), pp. 1439-1447. (doi: 10.1016/j.vaccine.2022.01.049) (PMID:35135700) (PMCID:PMC8884255)

Parry, H. et al. (2022) Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia. Journal of Hematology and Oncology, 15(1), 3. (doi: 10.1186/s13045-021-01219-7) (PMID:35000597) (PMCID:PMC8743056)

Dowell, A. C. et al. (2022) Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nature Immunology, 23(1), pp. 40-49. (doi: 10.1038/s41590-021-01089-8) (PMID:34937928) (PMCID:PMC8709786)

Davis, C. et al. (2021) Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathogens, 17(12), e1010022. (doi: 10.1371/journal.ppat.1010022) (PMID:34855916) (PMCID:PMC8639073)

Morgan, D. C. et al. (2021) Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalisation. Peptide Science, 113(4), e24217. (doi: 10.1002/pep2.24217) (PMID:33615115) (PMCID:PMC7883042)

Hughes, E. C. et al. (2021) Severe Acute Respiratory Syndrome Coronavirus 2 serosurveillance in a patient population reveals differences in virus exposure and antibody-mediated immunity according to host demography and healthcare setting. Journal of Infectious Diseases, 223(6), pp. 971-980. (doi: 10.1093/infdis/jiaa788) (PMID:33367847) (PMCID:PMC7798933)

Gilbert, M. et al. (2020) Distemper, extinction and vaccination of the Amur tiger. Proceedings of the National Academy of Sciences of the United States of America, 117(50), pp. 31954-31962. (doi: 10.1073/pnas.2000153117) (PMID:33229566) (PMCID:PMC7749280)

Abdullah, N. et al. (2018) Structure-guided identification of a non-human morbillivirus with zoonotic potential. Journal of Virology, 92(23), e01248-18. (doi: 10.1128/JVI.01248-18) (PMID:30232185) (PMCID:PMC6232486)

Hosie, M. J. , Techakriengkrai, N., Beczkowski, P. M., Harris, M., Logan, N. and Willett, B. (2017) The comparative value of feline virology research: can findings from the feline lentiviral vaccine be translated to humans? Veterinary Sciences, 4(1), 7. (doi: 10.3390/vetsci4010007)

Logan, N., Dundon, W. G., Diallo, A., Baron, M. D., Nyarobi, M. J., Cleaveland, S. , Keyyu, J., Fyumagwa, R., Hosie, M. J. and Willett, B. J. (2016) Enhanced immunosurveillance for animal morbilliviruses using vesicular stomatitis virus (VSV) pseudotypes. Vaccine, 34(47), pp. 5736-5743. (doi: 10.1016/j.vaccine.2016.10.010) (PMID:27742221) (PMCID:PMC5084683)

Holzer, B., Hodgson, S., Logan, N., Willett, B. and Baron, M. D. (2016) Protection of cattle against rinderpest by vaccination with wild-type but not attenuated strains of peste des petits ruminants virus. Journal of Virology, 90(10), pp. 5152-5162. (doi: 10.1128/jvi.00040-16) (PMID:26984722) (PMCID:PMC4859729)

Logan, N. et al. (2016) Efficient generation of vesicular stomatitis 1 virus (VSV)-pseudotypes bearing morbilliviral glycoproteins and their use in quantifying virus neutralising antibodies. Vaccine, 34(6), pp. 814-822. (doi: 10.1016/j.vaccine.2015.12.006) (PMID:6706278)

Beczkowski, P., Logan, N., McMonagle, E., Litster, A., Willett, B. J. and Hosie, M. J. (2015) An investigation of the breadth of neutralising antibody response in cats naturally infected with feline immunodeficiency virus. Journal of General Virology, 96(3), pp. 671-680. (doi: 10.1099/vir.0.071522-0) (PMID:25395594) (PMCID:PMC4336861)

Beczkowski, P. M., Techakriengkrai, N., Logan, N., McMonagle, E., Litster, A., Willett, B. J. and Hosie, M. J. (2014) Emergence of CD134 cysteine-rich domain 2 (CRD2)-independent strains of feline immunodeficiency virus (FIV) is associated with disease progression in naturally infected cats. Retrovirology, 11, p. 95. (doi: 10.1186/s12977-014-0095-7) (PMID:25430586) (PMCID:PMC4275942)

Willett, B.J. , Kraase, M., Logan, N., McMonagle, E., Varela, M. and Hosie, M.J. (2013) Selective expansion of viral variants following experimental transmission of a reconstituted feline immunodeficiency virus quasispecies. PLoS ONE, 8(1), e54871. (doi: 10.1371/journal.pone.0054871) (PMID:23372784) (PMCID:PMC3553009)

Teixeira, B.M., Logan, N., Samman, A., Miyashiro, S.I., Brandão, P.E., Willett, B.J. , Hosie, M.J. and Hagiwara, M.K. (2011) Isolation and partial characterization of Brazilian samples of feline immunodeficiency virus. Virus Research, 160(1-2), pp. 59-65. (doi: 10.1016/j.virusres.2011.05.007)

Dietrich, I., McMonagle, E. L., Petit, S. J., Vijayakrishnan, S. , Logan, N., Chan, C. N., Towers, G. J., Hosie, M. J. and Willett, B. J. (2011) Feline tetherin efficiently restricts release of feline immunodeficiency virus but not spreading of infection. Journal of Virology, 85(12), pp. 5840-5852. (doi: 10.1128/JVI.00071-11) (PMID:21490095) (PMCID:PMC3126296)

Samman, A., McMonagle, E.L., Logan, N., Willett, B.J. , Biek, R. and Hosie, M.J. (2011) Phylogenetic characterisation of naturally occurring feline immunodeficiency virus in the United Kingdom. Veterinary Microbiology, 150(3-4), pp. 239-247. (doi: 10.1016/j.vetmic.2011.01.027)

Willett, B. J., Kraase, M., Logan, N., McMonagle, E. L., Samman, A. and Hosie, M. J. (2010) Modulation of the virus-receptor interaction by mutations in the V5 loop of feline immunodeficiency virus (FIV) following in vivo escape from neutralising antibody. Retrovirology, 7(1), p. 38. (doi: 10.1186/1742-4690-7-38) (PMID:20420700) (PMCID:PMC2873508)

Kraase, M., Sloan, R., Klein, D., Logan, N., McMonagle, L., Biek, R. , Willett, B. J. and Hosie, M. J. (2010) Feline immunodeficiency virus env gene evolution in experimentally infected cats. Veterinary Immunology and Immunopathology, 134(1-2), pp. 96-106. (doi: 10.1016/j.vetimm.2009.10.015) (PMID:19897254)

Samman, A., Logan, N., McMonagle, E. L., Ishida, T., Mochizuki, M., Willett, B. J. and Hosie, M. J. (2010) Neutralization of feline immunodeficiency virus by antibodies targeting the V5 loop of Env. Journal of General Virology, 91(1), pp. 242-249. (doi: 10.1099/vir.0.015404-0)

Willett, B. J., McMonagle, E. L., Logan, N., Schneider, P. and Hosie, M. J. (2009) Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus. Molecular Immunology, 46(6), pp. 1020-1030. (doi: 10.1016/j.molimm.2008.08.271)

McEwan, W. A., McMonagle, E. L., Logan, N., Serra, R. C., Kat, P., Vandewoude, S., Hosie, M. J. and Willett, B. J. (2008) Genetically divergent strains of feline immunodeficiency virus from the domestic cat (Felis catus) and the African lion (Panthera leo) share usage of CD134 and CXCR4 as entry receptors. Journal of Virology, 82(21), pp. 10953-10958. (doi: 10.1128/JVI.01312-08)

Willett, B. J., McMonagle, E. L., Logan, N., Samman, A. and Hosie, M. J. (2008) A single site for N-linked glycosylation in the envelope glycoprotein of feline immunodeficiency virus modulates the virus-receptor interaction. Retrovirology, 5(77), (doi: 10.1186/1742-4690-5-77)

Willett, B.J., McMonagle, E.L., Logan, N., Spiller, O.B., Schneider, P. and Hosie, M.J. (2007) Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. Journal of Virology, 81(18), pp. 9665-9679. (doi: 10.1128/JVI.01020-07)

Logan, N., Graham, A., Zhao, X., Fisher, R., Maiti, B., Leone, G. and La Thangue, N. B. (2005) E2F-8: an E2F family member with a similar organization of DNA-binding domains to E2F-7. Oncogene, 24(31), pp. 5000-5004. (doi: 10.1038/sj.onc.1208703) (PMID:15897886)

Logan, N., Delavaine, L., Graham, A., Reilly, C., Wilson, J., Brummelkamp, T. R., Hijmans, E. M., Bernards, R. and La Thangue, N. B. (2004) E2F-7: a distinctive E2F family member with an unusual organization of DNA-binding domains. Oncogene, 23(30), pp. 5138-5150. (doi: 10.1038/sj.onc.1207649) (PMID:15133492)

Logan, N., Reilly, J.J., Grant, S. and Paton, J.Y. (2000) Resting heart rate definition and its effect on apparent levels of physical activity in young children. Medicine and Science in Sports and Exercise, 32(1), pp. 162-166.